CPP 102: ICI PROSTATE CANCER PRECEPTORSHIP

Multidisciplinary management, standards of care, optimal diagnostics, therapies, and future perspectives in the care of Prostate Cancer patients in sub-Saharan Africa.

Eldoret, Kenya

 8^th March 2022 – 14th April 2022

Training Duration: 6 weeks

Course Director: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist

Executive Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com Website: www.intercancer.com

Lead Course Faculty:

Dr. Kevin Makori MD, MMED

Clinical & Radiation Oncologist

Deputy Director of Programs

International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: kevin.makori@intercancer.com Website: www.intercancer.com

This educational activity is provided by International Cancer Institute (ICI) through the Blueprint Program

Accreditation of this course is by KMPDC, PPB, NCK, and COC

Target Audience

The primary target audience for this course comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; urologists; other health care professionals (internists, primary care physicians, pathologists, physicians-in-training, urology nurses, oncology nurses, nurse practitioners, pharmacists, physician assistants and nurse practitioners) involved and/or interested in the therapeutic management of patients with prostate cancer.

LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to:

1. Understand the Epidemiology of Prostate Cancer (Global)
2. To understand the role of screening for prostate cancer, including the evidence for and against the use of prostate-specific antigen (PSA) screening and the practical indications of serum PSA measurement in different clinical settings
3. recognize the role of pathological diagnosis, histologic grading, Gleason system, staging and prognostic factors in prostate cancer.
4. To understand the role of Surgery in the management of localized prostate cancer
5. To understand the role of radiotherapy in the management of localized prostate cancer
6. understand the management options for hormone sensitive metastatic prostate cancer
7. To understand the definition of castration-resistant prostate cancer (CRPC) and appreciate the novel therapies, their use and side effects profile in m-CRPC.
8. Discuss treatment options for patients with advanced prostate cancer, including secondary hormonal therapy, chemotherapy, immunotherapy, and radioisotope therapy
9. Understanding of how and when to use bone-targeted therapies and of the prevention and treatment of osteonecrosis of the jaw
10. To understand the role of multidisciplinary team in prostate cancer management
11. To understand the role of Palliative, supportive and survivorship care in prostate cancer management
12. Ability to diagnose and manage spinal cord compression, one of the most devastating complications of metastatic prostate cancer
13. To discuss clinical cases between faculty and participants

Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

The Program LECTURES

1. Orientation to the course (Prof. Chite Asirwa) Tuesday 8^th Mar 2022 3:00 – 4:00 PM EAT
2. Epidemiology of Prostate Cancer ( Achille Manirakiza) Tuesday 8^th Mar 2022 4:00 – 5:30 PM EAT
3. Screening and Diagnostic Workup for Prostate Cancer ( Sitna Mwanzi) Thursday 10^th Mar 2022 4:00-5:30 PM EAT
4. Role of Pathology in prostate cancer management ( Kibet Kibor) Tuesday 15^th Mar 2022 4:00-5:30 PM EAT
5. Pharmacology of Systemic Therapies in Prostate Cancer (Dr. Irene Weru) Thursday 17^th Mar 2022 4:00-5:30 PM EAT
6. Role of Surgery in the Management of Localized Prostate Cancer (Prof. Dinesh Pendharkar) Tuesday 22^nd Mar 2022 4:00-5:30 PM EAT
7. Role of radiotherapy in the management of localized prostate cancer (Verna Vanderpuye) Thursday 24^th Mar 2022 4:00- 5:30 PM EAT
8. Management of Hormone-sensitive Metastatic Prostate Cancer and use of Bone-targeted Therapies (Dr. Abdu Adem Yesufe) Tuesday 29^th April 2022 4:00-5:30 PM EAT
9. Treatment Options for Advanced Prostate Cancer, including Chemotherapy, Immunotherapy, and Radioisotope Therapy ( Achille Manirakiza) Thursday 31^st Mar 2022 4:00-5:30 PM EAT
10. Diagnosis and Management of Spinal Cord Compression in Prostate Cancer Patients ( Helena Musau) Tuesday 5^th Apr 2022 4:00-5:30 PM EAT
11. Management of Metastatic or Recurrent in Prostate Cancer ( Kevin Makori) Thursday 7^th Apr 2022 4:00-5:30 PM EAT
12. Supportive, Palliative and Survivorship care in Prostate Cancer Care ( Zipporah Ali) Tuesday 12^th Apr 2022 4:00 – 4:30 PM
13. Expert Panel Case discussions in prostate cancer management (Prof. Chite Asirwa & Expert Panelists) Wednesday 13^th Apr 2022 4:00-5:30 PM EAT
14. End of course examination (Education office) Thursday 14^th Apr 2022 4:00-5:30 PM EAT

CPP 101: ICI Prostate Cancer Preceptorship Course Schedule

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours). This program will start when the class is fully subscribed. The course cost is $200.00 for the entire course. There are few sponsorships available on a first-come basis for those who apply. Priority will be given to those working in cancer centers that have formal affiliations/Partnerships with the International Cancer Institute. Apply for sponsorship during the registration of the course

All those interested in registering to this course, please register your information on www.elearning.intercancer.com  if you have any questions or queries please send an email to education@intercancer.com or director@intercancer.com

For more information visit our website www.intercancer.com

International Cancer Institute (ICI) ©2022

Your Partner in Cancer Control in SSA